Multiple Sclerosis Trial, Not Yet Recruiting NCT07280871 Sponsor: Luxembourg Institute of Health Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Not Yet Recruiting

NCT07280871
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • A person must sign a consent form agreeing to take part in the trial.
  • Participants must be 18 years of age or older.
  • Participants must be willing and able to follow the study's requirements for its full duration, including attending visits, completing examinations, and providing data and samples.
  • Participants must have been diagnosed with multiple sclerosis (MS) according to recognised diagnostic guidelines (2017 or 2024 McDonald criteria), covering all forms of the condition, AND either be in the early stages of the disease (diagnosed within the last 3 years), or be attending hospital because their MS has worsened or their treatment needs to change, or be at a stage where their MS appears to be shifting toward a progressive form (as assessed by a doctor using a standard disability scale).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose MS diagnosis is uncertain or who do not meet the above diagnostic requirements may not be eligible.
  • People who have a condition — including a mental disability — that could make it difficult or impossible to follow the study procedures, attend visits, or complete questionnaires may not be eligible.
  • People who are not fluent in French, English, or German may not be eligible.
  • People with a known pregnancy at the time of joining the trial may not be eligible.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Krüger Rejko, Prof. Dr. MD, LIH

Phone: 352 26970-265

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Luxembourg Institute of Health
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 June 2032

Where this trial is recruiting

🇱🇺 Luxembourg

Primary endpoints

Identification of Clinical, Imaging, and Omics Signatures for MS Subtype Stratification

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov